Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus

IDrugs

Volumn 12, Issue 8, 2009, Pages 503-513

  Christensen, Mikkel ^a   Knop, Filip K ^a   Holst, Jens J ^b   Vilsboll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AQVE 0010; AVE 0010; AVE 010; AVE 0101; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; LIRAGLUTIDE; LIXISENATIDE; LYSINE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIOGLITAZONE; ROSE 010; UNCLASSIFIED DRUG; ZP 10;

ACUTE PANCREATITIS; ADD ON THERAPY; AREA UNDER THE CURVE; BILE DUCT DYSKINESIA; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CLINICAL TRIAL; DIABETES CONTROL; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RECEPTOR AFFINITY; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ANIMALS; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; PEPTIDES; RECEPTORS, GLUCAGON;

EID: 68549099651     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. 382195 Zealand Pharmaceuticals in joint venture with Elan. Zealand Pharmaceuticals A/S PRESS RELEASE 2000 July 28
2. 439499 Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B DIABETES 2001 50 7 1562-1570
3. 464785 Zealand Pharma reports successful phase I/IIa trial with ZP10 in type 2 diabetes patients. Zealand Pharma A/S PRESS RELEASE 2002 September 20
4. 475556 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mariou, Perfetti R ENDOCRINOLOGY 2002 143 11 4397-4408
5. 475562 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Zander M, Madsbad S, Lysgaard MJ, Holst JJ LANCET 2002 359 9309 824-830
6. 483810 Zealand regains full rights to ZP-10 from Elan. Zealand Pharma A/S PRESS RELEASE 2003 March 27
7. 494758 Aventis and Zealand Pharma sign licensing deal. Aventis SA PRESS RELEASE 2003 June 25
8. 511326 Drug development pipeline: AVE-0010, ImmunoGen TAPs, 109881. Aventis SA COMPANY COMMUNICATION 2003 November 03
9. 519005 Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS J PHARMACOL EXP THER 2003 307 2 490-496
10. 555709 Sanofi completes Aventis acquisition. Sanofi Synthelabo PRESS RELEASE 2004 August 20
11. 580626 Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP CIRCULATION 2004 109 8 962-965
12. 588294 sanofi-aventis finalize phase IIa clinical study with GLP-1 agonist for type 2 diabetes licensed from Zealand Pharma. sanof-aventis PRESS RELEASE 2005 March 03
13. 679424 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR BMJ (CLINICAL RES ED) 2000 321 7258 405-412
14. 744076 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD DIABETES CARE 2004 27 11 2628-2635
15. 744096 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD DIABETES CARE 2005 28 5 1083-1091
16. 760698 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W DIABETOLOGIA 1993 36 8 741-744
17. 805409 The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycemia. Werner U, Gerlach M, Hofmann M, Herling AW ANN MEET AM DIABETES ASSOC 2007 67 Abs 0486-P
18. 808243 Enhanced protection against cytokine- and fatty acid-induced apoptosis in Ins-1 β-cells by combined treatment with insulin glargine and the novel GLP-1 receptor agonist AVE0010. Tews D, Werner U, Eckel J ANN MEET AM DIABETES ASSOC 2007 67 Abs 0279-OR
19. 827063 Biology of incretins: GLP-1 and GIP. Baggio LL, Drucker DJ GASTROENTEROLOGY 2007 132 6 2131-2157
20. 830743 A promising R&D portfolio, well positioned to deliver future growth. sanof-aventis PRESS RELEASE 2007 September 17
21. 831970 Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Buse B, Klonoff C, Nielsen L, Guan CLIN THER 2007 29 1 139-153
22. 840972 Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, ANN INTERN MED 2005 143 8 559-569
23. 846494 The GLP-1 receptor agonist AVE0010 preserves β cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats - An isolated perfused pancreas study. Haschke G, Haag-Diergarten S, Werner U, Kramer W, Herling AW DIABETOLOGIA 2006 49 Suppl 1 Abs 0659
24. 846495 Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist AVE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia. Werner U, Gerlach M, Hofmann M, Herling AW DIABETOLOGIA 2006 49 Suppl 1 Abs 0656
25. 874585 The physiology of glucagon-like peptide 1. Holst JJ PHYSIOL REV 2007 87 4 1409-1439
26. 875837 Incretins, insulin secretion and type 2 diabetes mellitus. Vilsboll T, Holst JJ DIABETOLOGIA 2004 47 3 357-366
27. 876212 Phase III program for AVE0010/ZP10 licensed from Zealand Pharma A/S will begin in the first quarter of 2008. Zealand Pharma A/S PRESS RELEASE 2008 February 12
28. 880516 Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H DIABETES CARE 2004 27 5 1047-1053
29. 908298 GTP-010 as a therapeutic tool in IBS pain relief: Prospective, randomized, placebo-controlled study of a GLP-1 analog. Hellstrom PM, Kristensen J, Bjornsson E, Bytzer P, Hein J, Schambye H DIGESTIVE DIS WEEK 2008 Abs T1388
30. 909449 Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe. Novo Nordisk A/S PRESS RELEASE 2008 May 23
31. 914415 New diabetes compound AVE0010 showed clear dose response results with once-a-day injection in phase IIb study. sanofi-aventis PRESS RELEASE 2008 June 07
32. 914565 A dose-fnding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insuffciently controlled with metformin. Ratner RE, Rosenstock J, Boka G ANN MEET AM DIABETES ASSOC 2008 68 Abs 433-P
33. 914921 The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves β-cell function in human pancreatic islets. Werner U, Vandewalle B, Conte JK, Pattou F, Pruniaux M, Herling AW ANN MEET AM DIABETES ASSOC 2008 68 Abs 11-OR
34. 915031 Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients. Distiller L, Ruus PE ANN MEET AM DIABETES ASSOC 2008 68 Abs 520-P
35. 915385 Roche moves investigational diabetes drug, taspoglutide, into phase III clinical trials. Ipsen PRESS RELEASE 2008 June 10
36. 929979 Ipsen's first half 2008 sales, outlook for the full year 2008 and R&D pipeline update. PRESS RELEASE 2009 July 30
37. 930012 Second-quarter 2008 results. sanof-aventis PRESS RELEASE 2008 July 31
38. 931225 The use of exenatide in islet transplant recipients with chronic allograft dysfunction: Safety, effcacy, and metabolic effects. Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, Ponte GM, Cure PE, Monroy K, Mendez A, Selvaggi G, Ricordi C et al TRANSPLANTATION 2008 86 1 36-45
39. 931356 Islet β cell failure in type 2 diabetes. Prentki M, Nolan CJ J CLIN INVEST 2006 116 7 1802-1812
40. 931364 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W J CLIN INVEST 1993 91 1 301-307
41. 941663 Dose range effects of the new once daily GLP-1 receptor agonist AVE0010 added to metformin in type 2 diabetes. Rosenstock J, Ratner RE, Boka G DIABETOLOGIA 2008 51 Suppl 1 Abs 145
42. 953142 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang DL, Porter L LANCET 2008 372 9645 1240-1250
43. 953271 10-year follow-up of intensive glucose control in type 2 diabetes. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA N ENGL J MED 2008 359 15 1577-1589
44. 956212 Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. Werner U ANN ENDOCRINOL 2008 69 2 164-165
45. 956215 Effect of the glucagon-like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog. Moore MC, Werner U, Smith MS, Rodewald TD, Cherrington AD DIABETOLOGIA 2007 50 Suppl 1 Abs 0584
46. 960329 Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic β cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Tews D, Werner U, Eckel J HORM METAB RES 2008 40 3 172-180
47. 976021 Effcacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. Amori RE, Lau J, Pittas AG JAMA-J AM MED ASSOC 2007 298 2 194-206
48. 989413 sanofi-aventis Form 20-F 2008. sanofi-aventis FORM 20-F 2009 March 05
49. 995537 The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Kahn SE DIABETOLOGIA 2003 46 1 3-19
50. 995560 The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Pratley RE, Weyer C DIABETOLOGIA 2001 44 8 929-945
51. 995565 U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. No authors listed DIABETES 1995 44 11 1249-1258
52. 995569 Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL ANN INTERN MED 2007 147 6 386-399
53. 995571 The importance of β-cell management in type 2 diabetes. Standl E INT J CLIN PRACT SUPPL 2007 153 10-19
54. 995573 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. No authors listed LANCET 1998 352 9131 837-853
55. 995582 UKPDS and the legacy effect. Chalmers J, Cooper ME N ENGL J MED 2008 359 15 1618-1620
56. 995584 Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: A cardiologist's perspective. Cubbon R, Kahn M, Kearney MT INT J CLIN PRACT 2008 62 2 287-299
57. 996026 Effect of a multifactorial intervention on mortality in type 2 diabetes. Gaede P, Lund-Andersen H, Parving HH, Pedersen O N ENGL J MED 2008 358 6 580-591
58. 996028 Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B DIABETES CARE 2009 32 1 193-203
59. 996031 Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Ford ES, Li C, Little RR, Mokdad AH DIABETES CARE 2008 31 1 102-104
60. 996035 Attitudes of primary care providers toward diabetes: Barriers to guideline implementation. Larme AC, Pugh JA DIABETES CARE 1998 21 9 1391-1396
61. 996037 Insulin treatment and the problem of weight gain in type 2 diabetes. Carver C DIABETES EDUCATOR 2006 32 6 910-917
62. 996040 When oral agents fail: Practical barriers to starting insulin. Korytkowski M INT J OBESITY RELAT METAB DISORD 2002 26 Suppl 3 S18-S24
63. 996043 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Nauck M, Stockmann F, Ebert R, Creutzfeldt W DIABETOLOGIA 1986 29 1 46-52
64. 996045 International Union of Pharmacology. XXXV. The glucagon receptor family. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ PHARMACOL REV 2003 55 1 167-194
65. 996047 Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M CIRCULATION 2008 117 18 2340-2350
66. 996049 Glucagon-like peptide-1 prevents β cell glucolipotoxicity. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M DIABETOLOGIA 2004 47 5 806-815
67. 996071 Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Nystrom T, Gonon AT, Sjoholm A, Pernow J REGUL PEPT 2005 125 1-3 173-177
68. 996074 Glucagon-like peptide-1: A potent regulator of food intake in humans. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C GUT 1999 44 1 81-86
69. 996079 Glucagon-like peptide 1 improves the ability of the p-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Goke B DIABETES 1998 47 8 1259-1265
70. 996163 Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Hojberg PV, Zander M, Vilsboll T, Knop FK, Krarup T, Volund A, Holst JJ, Madsbad S DIABETOLOGIA 2008 51 4 632-640
71. 996169 Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ DIABETES 2001 50 3 609-613
72. 996173 Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. Vilsboll T, Agersø H, Krarup T, Holst JJ J CLIN ENDOCRINOL METAB 2003 88 1 220-224
73. 996174 Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M CLIN PHARMACOKINET 2007 46 7 577-588
74. 996227 Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ et al CLIN PHARMACOL THER 2005 78 6 675-688
75. 996232 Incretin hormone mimetics and analogues in diabetes therapeutics. Green BD, Flatt PR BEST PRACT RES CLIN ENDOCRINOL METAB 2007 21 4 497-516
76. 996236 Tolerability and effcacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME CLIN THER 2007 29 11 2333-2348
77. 996237 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD DIABETES CARE 2005 28 5 1092-1100
78. 996242 The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Zinman B, Hoogwerf BJ, Duran García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG ANN INTERN MED 2007 146 7 477-485
79. 996244 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B LANCET 2009 373 9662 473-481
80. 996444 Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers signifcantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. Marre M, Shaw J, Brandle M, Wan Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le-Thi TD, Colagiuri S DIABETES 2008 57 Abs 13-OR
81. 996450 Signifcantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: All as add-on to metformin and a sulfonylurea in type 2 diabetes. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic SS, Zdravkovic M, Ravin GM, Simo R DIABETES 2008 57 Abs 536-P
82. 996562 The GLP-1 receptor agonist AVE0010 abolishes OGTT induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycaemia. Werner U, Gerlach M, Hoffmann M, Herling AW DIABETES 2007 56 Suppl 1 129-130
83. 996596 Immunogenicity of xenopeptide hormone therapies. Schnabel CA, Fineberg SE, Kim DD PEPTIDES 2006 27 7 1902-1910
84. 996600 Treatment of type 2 diabetes with incretin-based therapies. Madsbad S LANCET 2009 373 9662 348-349
85. 996601 Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G et al J AM COLL CARDIOL 2009 53 6 501-510
86. 996602 New potential adjuncts to treatment of children with type 1 diabetes mellitus. Raman VS, Heptulla RA PEDIATR RES 2009 65 4 370-374
87. 996603 Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L DIABETES CARE 2005 28 11 2673-2679
88. 1006045 Exenatide once weekly new drug application submitted to FDA for type 2 diabetes. Amylin Pharmaceuticals Inc PRESS RELEASE 2009 May 05
89. 1006656 Information for healthcare professionals - Exenatide. FDA FDA GUIDELINES 2008 August 18
90. 1013515 Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patient with renal impairment. Liu Y, Ruus P ANN MEET AM DIABETES ASSOC 69 Abs 557-P
91. 1013547 Effect of the GLP-1 agonist AVE0010 on absorption of concomitant oral drugs. Liu Y, Ruus P ANN MEET AM DIABETES ASSOC 2009 69 Abs 495-P
92. 1013793 Post-meal effects of AVE0010, a once-daily GLP-1 receptor agonist, in type 2 diabetes inadequately controlled on metformin. Rosenstock J, Ratner RE, Boka G, Silvestre L ANN MEET AM DIABETES ASSOC 2009 69 Abs 564-P
93. 1018664 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group LANCET 1998 352 9131 837-853
94. 1018826 GLP-1 receptor agonists for type 2 diabetes. De Block CE, Van Gaal LF LANCET 2009 374 9683 4-6
95. 1020500 Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Xu G, Stoffers DA, Habener JF, Bonner-Weir S DIABETES 1998 48 12 2270-2276
96. 1020505 Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R ENDOCRINOLOGY 2003 144 12 5149-5158
97. 1020511 Gut peptides in the regulation of food intake and energy homeostasis. Murphy KG, Dhillo WS, Bloom SR ENDOCR REV 2006 27 7 719-727